Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis
Ning Kam, Kanila Perera, Ella Zomer, Danny Liew, Zanfina Ademi
Topics & Concepts
MedicineStatinPCSK9EvolocumabQuality-adjusted life yearEzetimibeCost effectivenessMarginal costHealth economicsInternal medicineEmergency medicineCholesterolPublic healthLipoproteinNursingMicroeconomicsLDL receptorEconomicsApolipoprotein A1Risk analysis (engineering)Lipoproteins and Cardiovascular HealthHealth Systems, Economic Evaluations, Quality of LifeAntiplatelet Therapy and Cardiovascular Diseases